Abstract：
The IFM/DFCI group reported that VRD induction followed by up-front autologous peripheral blood stem cell transplantation (ASCT) and maintenance therapy led to median PFS of 50 months, which established up-front ASCT as the standard of care even in the era of novel agents. We conducted a retrospective analysis on outcomes of patients who received triplet induction therapy followed by up-front ASCT at our institution. A total of 124 patients received ASCT between November 2016 and December 2021 at Japanese Red Cross Medical Center. Patient characteristics, treatment response before and after ASCT, and PFS and OS were retrospectively analyzed. VRD-based induction therapy was used for 94%. Among 118 evaluable patients, 116 (98%) received either consolidation and/or maintenance therapy. Best responses were ≥CR 77% and ≥VGPR 94%, respectively. Sixty-eight out of 104 patients achieved MRD-negativity by multiparameter FCM (<10-5). Five-year estimated PFS and OS were 54.7% and 80.2%, respectively. Age ≥65, high-risk cytogenetic abnormalities, and
摘要：
IFM/DFCI组报告说，VRD诱导后再进行自体外周血干细胞移植（ASCT）和维持治疗导致50个月的中位PFS，即使在新型药物时代，也将早期ASCT确立为护理标准。我们对在我们机构接受三联诱导治疗后接受早期ASCT的患者的预后进行了回顾性分析。2016年11月至2021年12月期间，共有124名患者在日本红十字会医疗中心接受了ASCT治疗。患者特征,ASCT前后的治疗反应，回顾性分析PFS和OS。94%采用基于VRD的诱导治疗。在118名可评估患者中，116人（98%）接受巩固和/或维持治疗。最佳反应≥CR77%，≥VGPR94%，分别。104例患者中有68例通过多参数FCM实现了MRD阴性（<10-5）。五年估计PFS和OS分别为54.7%和80.2%，分别。年龄≥65岁，高危细胞遗传学异常，ASCT前
